-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Safety with Medicine" is a humanistic case collection project cooperating with Beijing Chen Jumei Public Welfare Foundation and Yimaitong
.
The
series of interviews with physicians in urology will focus on the field of prostate cancer, and discuss the path of standardized diagnosis and treatment of prostate cancer based on real clinical needs.
and the importance of whole course management to clinical patients, highlighting the research spirit and professional quality of urological oncologists
.
Prostate cancer has now become the second most common tumor in men in the world, second only to lung cancer
.
The
incidence of prostate cancer in China is increasing year by year .
The diagnosis of early prostate cancer and comprehensive and systematic treatment plan have a great impact on the long-term prognosis of patients.
Therefore, prostate cancer derived from early screening, accurate diagnosis and comprehensive treatment is mostly The integrated construction of disciplinary diagnosis and treatment (MDT) is very necessary
.
In this issue, we invited Professor Huang Yi from Peking University Third Hospital to talk about the crucial role of the MDT model in promoting the development of precise treatment of prostate cancer, The development of prostate cancer treatment under the MDT model and the prospect for the
future.
Professor
Huang Yi, chief physician, professor, doctoral tutor Member of the Oncology Group of the Urology Branch of the Society Bone metastases, fractures, bone pain, hematuria and other symptoms do not take the initiative to come to see a doctor.
At this time, the patient has reached an advanced stage, which is very unfavorable for their treatment
.
"Currently, the detection of prostate cancer in domestic patients is localized.
More than 60% to 70% of patients with advanced and advanced metastases are patients, which requires us to gradually promote the early screening of prostate cancer
.
"Professor Huang Yi said, "This is far from what we have done at present
.
"The CSCO guidelines recommend that men over the age of 50, or men over the age of 45 with a family history of cancer, should be included in the high-risk group of prostate cancer, and they should undergo PSA screening every two years; at the same time, Huang Yi The professor believes that active promotion of community physical examination and popular science propaganda will help to promote the early screening of prostate cancer
.
Through screening, the detection rate of prostate cancer in high-risk groups can be improved, and the incidence and mortality of metastatic prostate cancer can be significantly reduced , Early screening, early diagnosis, and early treatment are one of the most effective ways to improve the 5-year survival rate of prostate cancer patients.
At the same time, actively carrying out comprehensive treatment in the MDT mode can bring the greatest benefits to patients
.
Most importantly, maximizing benefits for prostate cancer patients under the MDT model.
Multidisciplinary diagnosis and treatment (MDT) is a treatment model for difficult diseases.
After intensive discussion by multidisciplinary experts, individualized and optimal treatment plans for the disease are proposed
.
Professor Huang Yi believes that the advantage of the MDT model is that for complex diseases such as intermediate and advanced tumors, it usually involves multidisciplinary combined treatment.
It is difficult for a single specialist to grasp the comprehensive treatment progress of such complex diseases and achieve the ideal However, through the MDT model, experts from related disciplines are gathered together to formulate individualized treatment plans for individual patients, which can maximize the benefit of patients
.
Taking the MDT model of prostate cancer as an example, Professor Huang Yi introduced, The classic treatment methods of prostate cancer include surgery, internal radiotherapy, external radiotherapy, and endocrine therapy.
For patients who have entered the castration-resistant prostate cancer (CRPC) stage, chemotherapy, radionuclide therapy, targeted therapy, and immunotherapy can also be combined
.
For different stages and stages of prostate cancer, there are different combination methods and sequential treatment plans.
Combined therapy can achieve mutual synergy and achieve the best therapeutic effect
.
The
MDT model can be based on the characteristics of prostate cancer, accurately stratify, and formulate individualized combination therapy regimen
.
Pay attention to team training and development, and push the MDT model into the clinical "normal track".
In the establishment of the MDT model for prostate cancer, Professor Huang Yi gave us the example of Peking University Third Hospital
.
In order to ensure the maximum benefit of MDT, in addition to regular multidisciplinary consultations and discussions, Peking University Third Hospital has also managed the MDT team in a unified manner according to norms and procedures in recent years, conducting access review, process review and regular assessment.
For advanced prostate cancer that requires multidisciplinary treatment, the relevant departments have a fixed team of experts to discuss regularly and give the best comprehensive treatment plan
.
At the same time, the Department of Urology of Peking University Third Hospital also launched a continuing education class in the MDT model, inviting experts from the MDT team to give theoretical lectures, surgical demonstrations, case discussions, etc.
, in order to promote and learn from each other, and then promote and popularize MDT treatment mode
.
"The MDT model is particularly suitable for the diagnosis and treatment of tumors, because many tumors do require multiple methods of combined treatment, and a multidisciplinary team of experts is needed to make a treatment plan
.
" Professor Huang Yi said, "But the MDT model in China still needs further development.
Promotion, we still have a lot of work to do at this point
.
" The longer the "front", the greater the challenge, and the future of clinical treatment of prostate cancer can be expected The survival period of most patients with comprehensive treatment can reach more than 5 years.
Therefore, it is often necessary to manage it as a chronic disease in clinical practice, establish a patient data database, and follow up regularly
.
For these patients, how to manage, follow up, and formulate different treatment plans for different stages of patients are the current and future challenges faced by clinicians
.
However, compared with other urinary tract tumors, the treatment of prostate cancer has the fastest progress, and the research and investment of new clinical drugs for prostate cancer at home and abroad are also very large
.
Professor Huang Yi pointed out that prostate cancer has strong tumor heterogeneity, and the future development trend of prostate cancer treatment is more individualized, more precise and refined treatment
.
With the wide application of high-throughput next-generation genome sequencing and bioinformatic big data analysis, molecular stratification and precise treatment of tumors can be carried out
.
For example, for prostate cancer, susceptibility genes and various treatment pathways can be tested, and the test results can provide clinicians with accurate treatment options.
In this way, patients can maximize the benefits with minimal resource investment.
, to achieve the best therapeutic effect
.
At the end of the summary, Professor Huang Yi also put forward his own suggestions for clinicians who have just entered the field of urology
.
He believes that for urologists, the first is to strengthen the study of the basic theory and basic techniques of urology related diseases, and to understand the basic laws of diseases in this discipline; on this basis, they should also actively expand their knowledge.
Including understanding the progress of related disciplines, absorbing the relevant knowledge of multiple disciplines as much as possible, improving their comprehensive quality and comprehensive diagnosis and treatment of diseases
.
"In the field of medicine, a person does not become an expert in a day or two, but through years of accumulation, continuous learning, and continuous practice
.
Only in the process of repeated improvement can one further improve oneself.
This is a It's a long process
.
" Professor Huang Yi concluded
.
Review of Past Issues 1.
Dr.
Cai Yi | Walking against "swelling": Looking back on the past and making a voice in the field of prostate cancer 2.
Prof.
Tang Qi | "Diagnosis" insights: Talking about prostate cancer under the new diagnostic technology Development of the concept of diagnosis and treatment 3.
Prof.
Cui Feilun | "Talking about" the male commentary: Talking about the clinical diagnosis and treatment of prostate cancer "intrigue" with androgens Excellent doctors know why | Persistently seeking prescriptions for benevolence, cherishing patients with Fang Chengren’s heart medicine private Limited
.
The
series of interviews with physicians in urology will focus on the field of prostate cancer, and discuss the path of standardized diagnosis and treatment of prostate cancer based on real clinical needs.
and the importance of whole course management to clinical patients, highlighting the research spirit and professional quality of urological oncologists
.
Prostate cancer has now become the second most common tumor in men in the world, second only to lung cancer
.
The
incidence of prostate cancer in China is increasing year by year .
The diagnosis of early prostate cancer and comprehensive and systematic treatment plan have a great impact on the long-term prognosis of patients.
Therefore, prostate cancer derived from early screening, accurate diagnosis and comprehensive treatment is mostly The integrated construction of disciplinary diagnosis and treatment (MDT) is very necessary
.
In this issue, we invited Professor Huang Yi from Peking University Third Hospital to talk about the crucial role of the MDT model in promoting the development of precise treatment of prostate cancer, The development of prostate cancer treatment under the MDT model and the prospect for the
future.
Professor
Huang Yi, chief physician, professor, doctoral tutor Member of the Oncology Group of the Urology Branch of the Society Bone metastases, fractures, bone pain, hematuria and other symptoms do not take the initiative to come to see a doctor.
At this time, the patient has reached an advanced stage, which is very unfavorable for their treatment
.
"Currently, the detection of prostate cancer in domestic patients is localized.
More than 60% to 70% of patients with advanced and advanced metastases are patients, which requires us to gradually promote the early screening of prostate cancer
.
"Professor Huang Yi said, "This is far from what we have done at present
.
"The CSCO guidelines recommend that men over the age of 50, or men over the age of 45 with a family history of cancer, should be included in the high-risk group of prostate cancer, and they should undergo PSA screening every two years; at the same time, Huang Yi The professor believes that active promotion of community physical examination and popular science propaganda will help to promote the early screening of prostate cancer
.
Through screening, the detection rate of prostate cancer in high-risk groups can be improved, and the incidence and mortality of metastatic prostate cancer can be significantly reduced , Early screening, early diagnosis, and early treatment are one of the most effective ways to improve the 5-year survival rate of prostate cancer patients.
At the same time, actively carrying out comprehensive treatment in the MDT mode can bring the greatest benefits to patients
.
Most importantly, maximizing benefits for prostate cancer patients under the MDT model.
Multidisciplinary diagnosis and treatment (MDT) is a treatment model for difficult diseases.
After intensive discussion by multidisciplinary experts, individualized and optimal treatment plans for the disease are proposed
.
Professor Huang Yi believes that the advantage of the MDT model is that for complex diseases such as intermediate and advanced tumors, it usually involves multidisciplinary combined treatment.
It is difficult for a single specialist to grasp the comprehensive treatment progress of such complex diseases and achieve the ideal However, through the MDT model, experts from related disciplines are gathered together to formulate individualized treatment plans for individual patients, which can maximize the benefit of patients
.
Taking the MDT model of prostate cancer as an example, Professor Huang Yi introduced, The classic treatment methods of prostate cancer include surgery, internal radiotherapy, external radiotherapy, and endocrine therapy.
For patients who have entered the castration-resistant prostate cancer (CRPC) stage, chemotherapy, radionuclide therapy, targeted therapy, and immunotherapy can also be combined
.
For different stages and stages of prostate cancer, there are different combination methods and sequential treatment plans.
Combined therapy can achieve mutual synergy and achieve the best therapeutic effect
.
The
MDT model can be based on the characteristics of prostate cancer, accurately stratify, and formulate individualized combination therapy regimen
.
Pay attention to team training and development, and push the MDT model into the clinical "normal track".
In the establishment of the MDT model for prostate cancer, Professor Huang Yi gave us the example of Peking University Third Hospital
.
In order to ensure the maximum benefit of MDT, in addition to regular multidisciplinary consultations and discussions, Peking University Third Hospital has also managed the MDT team in a unified manner according to norms and procedures in recent years, conducting access review, process review and regular assessment.
For advanced prostate cancer that requires multidisciplinary treatment, the relevant departments have a fixed team of experts to discuss regularly and give the best comprehensive treatment plan
.
At the same time, the Department of Urology of Peking University Third Hospital also launched a continuing education class in the MDT model, inviting experts from the MDT team to give theoretical lectures, surgical demonstrations, case discussions, etc.
, in order to promote and learn from each other, and then promote and popularize MDT treatment mode
.
"The MDT model is particularly suitable for the diagnosis and treatment of tumors, because many tumors do require multiple methods of combined treatment, and a multidisciplinary team of experts is needed to make a treatment plan
.
" Professor Huang Yi said, "But the MDT model in China still needs further development.
Promotion, we still have a lot of work to do at this point
.
" The longer the "front", the greater the challenge, and the future of clinical treatment of prostate cancer can be expected The survival period of most patients with comprehensive treatment can reach more than 5 years.
Therefore, it is often necessary to manage it as a chronic disease in clinical practice, establish a patient data database, and follow up regularly
.
For these patients, how to manage, follow up, and formulate different treatment plans for different stages of patients are the current and future challenges faced by clinicians
.
However, compared with other urinary tract tumors, the treatment of prostate cancer has the fastest progress, and the research and investment of new clinical drugs for prostate cancer at home and abroad are also very large
.
Professor Huang Yi pointed out that prostate cancer has strong tumor heterogeneity, and the future development trend of prostate cancer treatment is more individualized, more precise and refined treatment
.
With the wide application of high-throughput next-generation genome sequencing and bioinformatic big data analysis, molecular stratification and precise treatment of tumors can be carried out
.
For example, for prostate cancer, susceptibility genes and various treatment pathways can be tested, and the test results can provide clinicians with accurate treatment options.
In this way, patients can maximize the benefits with minimal resource investment.
, to achieve the best therapeutic effect
.
At the end of the summary, Professor Huang Yi also put forward his own suggestions for clinicians who have just entered the field of urology
.
He believes that for urologists, the first is to strengthen the study of the basic theory and basic techniques of urology related diseases, and to understand the basic laws of diseases in this discipline; on this basis, they should also actively expand their knowledge.
Including understanding the progress of related disciplines, absorbing the relevant knowledge of multiple disciplines as much as possible, improving their comprehensive quality and comprehensive diagnosis and treatment of diseases
.
"In the field of medicine, a person does not become an expert in a day or two, but through years of accumulation, continuous learning, and continuous practice
.
Only in the process of repeated improvement can one further improve oneself.
This is a It's a long process
.
" Professor Huang Yi concluded
.
Review of Past Issues 1.
Dr.
Cai Yi | Walking against "swelling": Looking back on the past and making a voice in the field of prostate cancer 2.
Prof.
Tang Qi | "Diagnosis" insights: Talking about prostate cancer under the new diagnostic technology Development of the concept of diagnosis and treatment 3.
Prof.
Cui Feilun | "Talking about" the male commentary: Talking about the clinical diagnosis and treatment of prostate cancer "intrigue" with androgens Excellent doctors know why | Persistently seeking prescriptions for benevolence, cherishing patients with Fang Chengren’s heart medicine private Limited